Compare
Allogene Therapeutics, Inc. vs Amgen Inc vs Bio-Techne Corp vs Gilead Sciences, Inc.
| Latest fiscal year | Allogene Therapeutics, Inc. ALLO | Amgen Inc AMGN | Bio-Techne Corp TECH | Gilead Sciences, Inc. GILD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $0 | $36.75B | $1.22B | $29.44B |
| Revenue growth (YoY) | -100.0% | +10.0% | -0.4% | +2.4% |
| Gross margin | n/a | 67.2% (computed) | 65.8% | 78.8% (computed) |
| Operating margin | n/a | 24.7% | 20.7% | 34.0% |
| Net margin | n/a | 21.0% | 15.0% | 28.9% |
| Net income | -$190.89M | $7.71B | $181.86M | $8.51B |
| EPS (Diluted) | -$0.87 | $14.23 | $1.16 | $6.78 |
| Operating cash flow | -$149.25M | $9.96B | $292.07M | $10.02B |
| Free cash flow | -$149.63M | $8.10B | $263.22M | $9.46B |
| Cash & equivalents | $51.69M | $9.13B | $264.71M | n/a |
| Total assets | $415.90M | $90.59B | $2.59B | $59.02B |
| Total liabilities | $123.36M | n/a | n/a | n/a |
| Shareholders' equity | $292.54M | $8.66B | $2.11B | $22.62B |
| Return on year-end equity | -65.3% | 89.1% | 8.6% | 37.6% |
| Shares outstanding | 229.41M | 538.80M | 156.10M | 1.24B |
Revenue, most recent five fiscal years
| Fiscal year | Allogene Therapeutics, Inc. | Amgen Inc | Bio-Techne Corp | Gilead Sciences, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $1.22B Ended 2026-06-30 | $29.44B Ended 2025-12-31 |
| 1 year earlier | $22.0K Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $1.22B Ended 2025-06-30 | $28.75B Ended 2024-12-31 |
| 2 years earlier | $95.0K Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $1.16B Ended 2024-06-30 | $27.12B Ended 2023-12-31 |
| 3 years earlier | $156.0K Ended 2022-12-31 | $26.32B Ended 2022-12-31 | $1.14B Ended 2023-06-30 | $27.28B Ended 2022-12-31 |
| 4 years earlier | $114.09M Ended 2021-12-31 | $25.98B Ended 2021-12-31 | $1.11B Ended 2022-06-30 | $27.30B Ended 2021-12-31 |